Low remission rates but long drug survival in rheumatoid arthritis patients treated with infliximab or etanercept: results from the nationwide Danish DANBIO database

Scand J Rheumatol. Mar-Apr 2007;36(2):151-4. doi: 10.1080/03009740601089267.
No abstract available

Publication types

  • Evaluation Study
  • Letter

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antirheumatic Agents / therapeutic use*
  • Arthritis, Rheumatoid / drug therapy*
  • Denmark
  • Etanercept
  • Humans
  • Immunoglobulin G / therapeutic use*
  • Infliximab
  • Kaplan-Meier Estimate
  • Methotrexate / therapeutic use
  • Patient Compliance
  • Product Surveillance, Postmarketing
  • Prospective Studies
  • Receptors, Tumor Necrosis Factor / therapeutic use*
  • Registries / statistics & numerical data*
  • Remission Induction
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*

Substances

  • Antibodies, Monoclonal
  • Antirheumatic Agents
  • Immunoglobulin G
  • Receptors, Tumor Necrosis Factor
  • Tumor Necrosis Factor-alpha
  • Infliximab
  • Etanercept
  • Methotrexate